Relevance of Allergy in Adult Asthma

Part of the following topical collections:
  1. Topical Collection on Allergens


Recent studies on asthma have demonstrated multiple phenotypes, based on the clinical characteristics of the disease. With the current interest in personalized medicine, the question arises whether the presence of allergic sensitization has any relevance for these phenotypes and the management of asthma. This review will examine the current knowledge of asthma phenotypes and the impact of atopy on asthma diagnosis and severity in adults. In addition, this review will address whether therapies targeted at the atopic axis help improve asthma outcomes, including lung function indices and exacerbations.


Asthma, Allergy Adult asthma Atopy Phenotype Asthma control Airway inflammation One airway hypothesis 


Compliance with Ethics Guidelines

Conflict of Interest

Sameer K. Mathur has served as a consultant for TEVA, has received grant support from the National Institutes of Health, and served as vice president of the Wisconsin Allergy Society and chair of the AAAAI Asthma and Allergic Diseases in the Elderly Committee.

Ravi K. Viswanathan declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet. 2006;368(9537):804–13.PubMedCrossRefGoogle Scholar
  2. 2.•
    Moore WC, Meyers DA, Wenzel SE, Teague WG, Li HS, Li XN, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med. 2010;181(4):315–23. This article is the first to describe phenotypes of asthma derived using statistical methods that allowed the clinical features of patients to designate “clusters” of patients. PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Schatz M, Hsu JW, Zeiger RS, Chen W, Dorenbaum A, Chipps BE, et al. Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2013. doi: 10.1016/j.jaci.2013.10.006.
  4. 4.
    Kim TB, Jang AS, Kwon HS, Park JS, Chang YS, Cho SH, et al. Identification of asthma clusters in two independent Korean adult asthma cohorts. Eur Respir J. 2013;41(6):1308–14.PubMedCrossRefGoogle Scholar
  5. 5.
    Weinmayr G, Keller F, Kleiner A, du Prel JB, Garcia-Marcos L, Batlles-Garrido J, et al. Asthma phenotypes identified by latent class analysis in the ISAAC phase II Spain study. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2013;43(2):223–32.CrossRefGoogle Scholar
  6. 6.
    Lotvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127(2):355–60.PubMedCrossRefGoogle Scholar
  7. 7.
    Ozol D, Koca C, Mete E, Yigitoglu R. Influence of atopy on asthma severity in adult female patients. J Investig Allergol Clin Immunol. 2008;18(1):36–40.PubMedGoogle Scholar
  8. 8.
    Ponte EV, Souza-Machado A, Souza-Machado C, Franco R, Cruz AA. Atopy is not associated with poor control of asthma. J Asthma Off J Assoc Care Asthma. 2012;49(10):1021–6.Google Scholar
  9. 9.
    Schwindt CD, Tjoa T, Floro JN, McLaren C, Delfino RJ. Association of atopy to asthma severity and medication use in children. J Asthma Off J Assoc Care Asthma. 2006;43(6):439–46.CrossRefGoogle Scholar
  10. 10.
    Carroll WD, Lenney W, Child F, Strange RC, Jones PW, Whyte MK, et al. Asthma severity and atopy: how clear is the relationship? Arch Dis Child. 2006;91(5):405–9.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Rasmussen F, Taylor DR, Flannery EM, Cowan JO, Greene JM, Herbison GP, et al. Risk factors for hospital admission for asthma from childhood to young adulthood: a longitudinal population study. J Allergy Clin Immunol. 2002;110(2):220–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Zimmerman B, Feanny S, Reisman J, Hak H, Rashed N, McLaughlin FJ, et al. Allergy in asthma. I. The dose relationship of allergy to severity of childhood asthma. J Allergy Clin Immunol. 1988;81(1):63–70.PubMedCrossRefGoogle Scholar
  13. 13.•
    Simpson A, Tan VY, Winn J, Svensen M, Bishop CM, Heckerman DE, et al. Beyond atopy: multiple patterns of sensitization in relation to asthma in a birth cohort study. Am J Respir Crit Care Med. 2010;181(11):1200–6. This article provides evidence for a novel concept that patterns of allergic sensitization may have implications for risk of asthma development. PubMedCrossRefGoogle Scholar
  14. 14.
    Holt PG, Sly PD. Viral infections and atopy in asthma pathogenesis: new rationales for asthma prevention and treatment. Nat Med. 2012;18(5):726–35.PubMedCrossRefGoogle Scholar
  15. 15.
    Kusel MM, Kebadze T, Johnston SL, Holt PG, Sly PD. Febrile respiratory illnesses in infancy and atopy are risk factors for persistent asthma and wheeze. Eur Respir J. 2012;39(4):876–82.PubMedCrossRefGoogle Scholar
  16. 16.
    Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med. 2008;178(7):667–72.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Kurukulaaratchy RJ, Matthews S, Holgate ST, Arshad SH. Predicting persistent disease among children who wheeze during early life. Eur Respir J. 2003;22(5):767–71.PubMedCrossRefGoogle Scholar
  18. 18.
    Oddy WH, de Klerk NH, Sly PD, Holt PG. The effects of respiratory infections, atopy, and breastfeeding on childhood asthma. Eur Respir J. 2002;19(5):899–905.PubMedCrossRefGoogle Scholar
  19. 19.
    Yarnell JW, Stevenson MR, MacMahon J, Shields M, McCrum EE, Patterson CC, et al. Smoking, atopy and certain furry pets are major determinants of respiratory symptoms in children: the International Study of Asthma and Allergies in Childhood Study (Ireland). Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2003;33(1):96–100.CrossRefGoogle Scholar
  20. 20.
    Van Asperen PP, Mukhi A. Role of atopy in the natural history of wheeze and bronchial hyper-responsiveness in childhood. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 1994;5(3):178–83.CrossRefGoogle Scholar
  21. 21.
    Anderson HR, Pottier AC, Strachan DP. Asthma from birth to age 23: incidence and relation to prior and concurrent atopic disease. Thorax. 1992;47(7):537–42.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Tollerud DJ, OConnor GT, Sparrow D, Weiss ST. Asthma, hay-fever, and phlegm production associated with distinct patterns of allergy skin-test reactivity, eosinophilia, and serum Ige levels–the Normative Aging Study. Am Rev Respir Dis. 1991;144(4):776–81.PubMedCrossRefGoogle Scholar
  23. 23.
    Kerkhof M, Dubois AE, Postma DS, Schouten JP, de Monchy JG. Role and interpretation of total serum IgE measurements in the diagnosis of allergic airway disease in adults. Allergy. 2003;58(9):905–11.PubMedCrossRefGoogle Scholar
  24. 24.
    Busse PJ, Cohn RD, Salo PM, Zeldin DC. Characteristics of allergic sensitization among asthmatic adults older than 55 years: results from the National Health and Nutrition Examination Survey, 2005–2006. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2013;110(4):247–52.CrossRefGoogle Scholar
  25. 25.
    Rijssenbeek-Nouwens LH, Bel EH. High-altitude treatment: a therapeutic option for patients with severe, refractory asthma? Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2011;41(6):775–82.CrossRefGoogle Scholar
  26. 26.
    Boner AL, Niero E, Antolini I, Valletta EA, Gaburro D. Pulmonary function and bronchial hyperreactivity in asthmatic children with house dust mite allergy during prolonged stay in the Italian Alps (Misurina, 1756 m). Ann Allergy. 1985;54(1):42–5.PubMedGoogle Scholar
  27. 27.
    Simon HU, Grotzer M, Nikolaizik WH, Blaser K, Schoni MH. High altitude climate therapy reduces peripheral blood T lymphocyte activation, eosinophilia, and bronchial obstruction in children with house-dust mite allergic asthma. Pediatr Pulmonol. 1994;17(5):304–11.PubMedCrossRefGoogle Scholar
  28. 28.
    Platts-Mills TA, Tovey ER, Mitchell EB, Moszoro H, Nock P, Wilkins SR. Reduction of bronchial hyperreactivity during prolonged allergen avoidance. Lancet. 1982;2(8300):675–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Gotzsche PC, Johansen HK. House dust mite control measures for asthma. Cochrane Database Syst Rev. 2008;2, CD001187.PubMedGoogle Scholar
  30. 30.••
    Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010;(8):CD001186. doi: 10.1002/14651858.CD001186.pub2. This review article evaluates all the studies examining the use of SCIT in the treatment of asthma.
  31. 31.••
    Lin SY, Erekosima N, Kim JM, Ramanathan M, Suarez-Cuervo C, Chelladurai Y, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA. 2013;309(12):1278–88. This review article evaluates all the studies examining the use of SLIT in the treatment of asthma. PubMedCrossRefGoogle Scholar
  32. 32.
    Jayaram L, Pizzichini MM, Cook RJ, Boulet LP, Lemiere C, Pizzichini E, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J. 2006;27(3):483–94.PubMedCrossRefGoogle Scholar
  33. 33.
    Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–84.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Nair P, Pizzichini MMM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360(10):985–93.PubMedCrossRefGoogle Scholar
  35. 35.
    Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365(12):1088–98.PubMedCrossRefGoogle Scholar
  36. 36.
    Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–66.PubMedCrossRefGoogle Scholar
  37. 37.
    Humbert M, Durham SR, Ying S, Kimmitt P, Barkans J, Assoufi B, et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against “intrinsic” asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med. 1996;154(5):1497–504.PubMedCrossRefGoogle Scholar
  38. 38.
    Ying S, Humbert M, Barkans J, Corrigan CJ, Pfister R, Menz G, et al. Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol. 1997;158(7):3539–44.PubMedGoogle Scholar
  39. 39.
    Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Della Cioppa G, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184–90.PubMedCrossRefGoogle Scholar
  40. 40.
    MacGlashan Jr DW, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158(3):1438–45.PubMedGoogle Scholar
  41. 41.•
    Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taille C, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest. 2013;144(2):411–9. This article provides clinical evidence that the treatment of traditional allergic inflammatory pathways with omalizumab can also benefit patients without allergic sensitivity. PubMedCrossRefGoogle Scholar
  42. 42.
    Volcheck GW. Does rhinitis lead to asthma? Evidence for the one-airway hypothesis. Postgrad Med. 2004;115(5):65–8.PubMedGoogle Scholar
  43. 43.
    Bush RK. Indoor allergens, environmental avoidance, and allergic respiratory disease. Allergy Asthma Proc Off J Reg State Allergy Soc. 2008;29(6):575–9.CrossRefGoogle Scholar
  44. 44.
    Eggleston PA. Improving indoor environments: reducing allergen exposures. J Allergy Clin Immunol. 2005;116(1):122–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.University of Wisconsin School of MedicineMadisonUSA
  2. 2.William S. Middleton Veterans HospitalMadisonUSA
  3. 3.Division of Allergy, Immunology and Critical Care, Department of MedicineUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA

Personalised recommendations